Sarasin & Partners LLP grew its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 5.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,187,948 shares of the biopharmaceutical company’s stock after buying an additional 252,062 shares during the quarter. Pfizer makes up 3.4% of Sarasin & Partners LLP’s portfolio, making the stock its 4th largest position. Sarasin & Partners LLP owned about 0.31% of Pfizer worth $174,263,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Northstar Group Inc. lifted its position in Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 35 shares in the last quarter. River Wealth Advisors LLC lifted its position in Pfizer by 0.3% during the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after buying an additional 55 shares in the last quarter. Meridian Wealth Management LLC lifted its position in Pfizer by 0.5% during the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 57 shares in the last quarter. Stone House Investment Management LLC lifted its position in Pfizer by 0.9% during the 1st quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after buying an additional 66 shares in the last quarter. Finally, Telemus Capital LLC lifted its position in Pfizer by 0.5% during the 2nd quarter. Telemus Capital LLC now owns 17,888 shares of the biopharmaceutical company’s stock worth $601,000 after buying an additional 92 shares in the last quarter. 69.36% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now owns 132,124 shares in the company, valued at approximately $4,492,216. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sally Susman sold 38,230 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The disclosure for this sale can be found here. Insiders have sold a total of 374,621 shares of company stock worth $12,796,098 in the last quarter. 0.06% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: This article was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://theolympiareport.com/2017/11/18/pfizer-inc-pfe-holdings-raised-by-sarasin-partners-llp.html.

Pfizer, Inc. (NYSE:PFE) opened at $35.37 on Friday. Pfizer, Inc. has a 52-week low of $30.51 and a 52-week high of $36.78. The stock has a market cap of $211,960.00, a P/E ratio of 14.15, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the business posted $0.61 EPS. sell-side analysts expect that Pfizer, Inc. will post 2.6 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. Pfizer’s dividend payout ratio is 78.53%.

PFE has been the topic of several analyst reports. BMO Capital Markets reissued a “buy” rating and set a $37.00 price target on shares of Pfizer in a research report on Wednesday, September 6th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a research report on Wednesday, September 13th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Tuesday, October 3rd. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Finally, ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and an average price target of $38.48.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.